The collaboration is expected to provide key expertise to reinforce the development of JUNO-Checked technology, particularly in go-to-market strategy, regulatory processes and overall business development. As part of the agreement, Scalania will leverage its team of subject matter experts with two decades of experience in the field to provide hands-on support in critical areas.

Under the terms of the agreement, Scalania will provide ongoing strategic support to Spermosens in the following areas:

• Market strategy support:
  • Regular updates on industry trends, competitor insights and market shifts.
  • Assistance in developing business models, market entry strategies and positioning plans.
  • Advisory on business development.

• R&D and regulatory strategy support:
  • Guidance on compliance requirements for business expansion and product launches.
  • Support in establishing a partner network to ensure smooth regulatory processes.
  • Direct engagement from Scalania’s subject matter experts with two decades of experience in market strategy and regulatory affairs, ensuring best-in-class support.

Tore Duvold, CEO of Spermosens, comments: " I'm very pleased to share this exciting collaboration with Scalania. Their expertise in regulatory matters and market strategy will be an important support for us as we continue to develop and bring our JUNO-Checked technology to a broader market. This partnership will strengthen our ability to navigate the regulatory landscape and improve our market positioning, helping us move closer to our goal of making a meaningful impact in male fertility diagnostics"

Klaas Rackebrandt, CEO of Scalania, comments: "We are delighted to partner with Spermosens and support their innovative journey. Our extensive experience in navigating regulatory environments, executing effective market strategies, and providing direct expert support aligns perfectly with Spermosens' ambitions. Furthermore, with Scalania, we bring access to the broader UNITY Innovation Alliance network of over 800 experts, spanning various industries and disciplines. This invaluable ecosystem enables us to provide Spermosens with cross-industry insights, strategic connections, and specialized expertise to further accelerate their growth and market success."

This strategic collaboration reinforces Spermosens’ commitment to advancing its diagnostic solutions for male fertility assessment and positions the Company for success in a large and growing market.

About Spermosens AB
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checkedproduct aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market.

About Scalania AG
Scalania, part of the UNITY Innovation Alliance group, is a corporate finance boutique specializing in long-term project support for emerging companies in the MedTech sector. By combining expertise in corporate finance with a strong focus on MedTech, Scalania integrates both engineering and financial backgrounds to provide strategic support. With deep knowledge in market strategy, regulatory guidance, and business development, Scalania helps companies across Europe and beyond achieve sustainable growth and navigate complex industry challenges.

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com